MedPath

Identification of Biomarkers for Obstructive Sleep Apnoea Syndrome

Completed
Conditions
Obstructive Sleep Apnoea Syndrome
Registration Number
NCT02043483
Lead Sponsor
Universidade Nova de Lisboa
Brief Summary

Untreated Obstructive Sleep Apnea Syndrome (OSAS) has long-term complications, namely metabolic imbalances (obesity, dislipidemia, type 2 diabetes mellitus). Until now, no molecular markers for this physiopathological connection have been identified.

This project aims to determine non-invasive biomarkers that may allow better comprehension of the metabolic consequences of OSAS, as well as assess the effect of Continuous positive airway pressure (CPAP) on these metabolic parameters.

This project will integrate the clinical, metabolic, genetic/proteomic and biologic systems to further explore the mechanisms behind OSAS, as well as the effect of the treatment with CPAP.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
120
Inclusion Criteria
  • Male
  • 25-60 years
  • Mild/Moderate/Severe OSAS
Exclusion Criteria
  • Female
  • Other sleep disorders
  • Previous CPAP therapy
  • Type 1 diabetes mellitus
  • Familiar Dyslipidemia
  • Severe organ pathology
  • Acute disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of patients with clinical improvement6 months

Treatment efficacy of CPAP will be assessed at the end of treatment through a clinical observation.

Secondary Outcome Measures
NameTimeMethod
Frequency of occurence of biomarkers6 months

Using Mass Spectrometric Immunoassay, we will identify which biomarkers have a positive association with long-term treatment effect.

Trial Locations

Locations (1)

Centro Hospitalar Lisboa Norte

🇵🇹

Lisbon, Portugal

© Copyright 2025. All Rights Reserved by MedPath